MedTech’s great unbundling.
How does marketing keep physician trust intact when the company behind the device is about to change?
This week’s Marketing Story Behind Medtech News isn’t one headline. It’s a pattern across nearly every major player in the industry.
And we think there’s a physician trust problem hiding inside the M&A news.
J&J is reportedly close to selling DePuy Synthes to private equity. Teleflex already sold its OEM division to two PE firms. Stryker, Medtronic, and BD have all shed business units in the past two years. Bain found that spin-offs and divestitures made up more than a third of strategic medtech deal value in 2025; a clear break from historical norms. (Full report: https://lnkd.in/gzUcxjFY)
Corporate Development is driving these deals. But marketers should be paying attention, too.
Physician trust in a device isn’t just about the device. It’s built on the company behind it: clinical relationships, a track record of standing behind products, visible commitment to long-term R&D. That’s part of what a rep is really selling in the OR.
Private equity ownership doesn’t erase that trust overnight, but it does change the story from “backed by 50 years of innovation” to “owned by a firm optimizing for exit.” Physicians notice when a familiar name changes hands.
So here’s what I’d be doing if I were on the marketing team going through this:
• Don’t wait for physicians to ask what changed.
• Get ahead of it.
• Reaffirm what stays the same (the clinical team, the support, the pipeline) before silence lets them assume the worst.